Guddi Singh, MB BChir, MPH, John Owens, MA, PhD, and Alan Cribb, PhD
Co-creation initiatives in health care have potential to support health equity but require a redistribution of power and a common vision in order to succeed.
AMA J Ethics. 2017;19(11):1132-1138. doi:
10.1001/journalofethics.2017.19.11.msoc1-1711.
This digital still from a narrated animated portrait depicts a woman overwhelmed by her body’s failure and by a health care system’s failure to care well.
AMA J Ethics. 2021;23(8):E658-659. doi:
10.1001/amajethics.2021.658.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Differentiating between best palliative care options and the curative and palliative potential of surgery is key to developing dual intentional clarity.
AMA J Ethics. 2021;23(10):E766-771. doi:
10.1001/amajethics.2021.766.
Pringl Miller, MD, Preeti R. John, MD, MPH, and Sabha Ganai, MD, PhD, MPH
A surgeon’s duty is to identify goals of care, including those about quality of life, from a patient’s perspective and to consider how to achieve them.
AMA J Ethics. 2021;23(10):E778-782. doi:
10.1001/amajethics.2021.778.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"